Teriparatide for Tibial Stress Fracture Recovery in Soldiers

This study, called Teriparatide STRONG, is looking at whether a medication called teriparatide can help soldiers recover faster from a specific type of bone injury called a diaphyseal tibial stress fracture (a break in the shin bone). Teriparatide is a synthetic (man-made) parathyroid hormone that has been shown to help build bone. Researchers want to see if it can reduce the time it takes for soldiers to return to duty and prevent these fractures from happening again. You might be able to join if you are an active U.S. Army soldier at Fort Jackson with this type of stress fracture, are skeletally mature, willing to inject the medication yourself, and want to continue your military service. The study will compare teriparatide to a placebo (a sugar solution). The main goals are to see how long it takes to return to full activity and to evaluate the long-term effects of teriparatide on recovery and injury recurrence over three years. The current status of this study is unclear.

Study design
This is a randomized, controlled study designed to enroll 183 participants. Participants will receive either teriparatide or a placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for three years to evaluate long-term effects and injury recurrence.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04589819

Fracture Recovery for Returning to Duty (Teriparatide STRONG)

Enrolling by Invitation
PHASE4All AgesInterventionalTreatment
University of South Carolina
~183 participants
Updated 2023-02-13 on ClinicalTrials.gov
What's tested:TeriparatidePlacebos

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time from diagnosis to full return to activity
Measured over 3 years
+3 more outcomes measured
Stress Fracture of Tibia or Fibula
1 sites across 1 states
South Carolina1
  • James B Jackson, MD · PRINCIPAL_INVESTIGATOR · University of South Carolina School of Medicine

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Soldiers actively enlisted in the U.S. Army attached to basic training unit at Fort Jackson
Soldiers diagnosed with a tibial diaphyseal BSI requiring convalescent leave
Skeletally mature
Willing to self-administer study medication
Desire to continue their military commitment

Exclusion

History of any form of cancer
Currently pregnant
Paget's disease of bone
Unexplained elevations of alkaline phosphatase (elevations in alkaline phosphatase may signal undiagnosed Paget's disease of bone)
Pediatric and young adult patients with open epiphyses
Prior external beam or implant radiation therapy involving the skeleton
Recent (within the last 6 months) urolithiasis (kidney stones)
Elevated serum calcium, alkaline phosphatase or uric acid
Orthostatic hypotension
  • Time from diagnosis to full return to activity3 years

    Time to full return to activity will be measured in days from diagnosis of a bone stress injury to obtaining a passing Army Combat Fitness Test (ACFT) score.

  • Evaluation of long-term effects of the administration of teriparatide3 years

    The investigators will evaluate the long-term effects of the administration of teriparatide by following the study enrollees for a 1-year period after the completion of the study drug. The team will determine the incidence of drug related side effects. This data will be based on study nurse records during drug administration and from their data contained in the participants' Electronic Medical Records.

  • Evaluation of long-term effects of the administration of teriparatide on injury recurrence3 years

    The investigators will evaluate the long-term effects of the administration of teriparatide by following the study enrollees for a 1-year period after the completion of the study drug. The team will determine the incidence of injury recurrence as defined by lost duty time.

  • Evaluation of long-term effects of the administration of teriparatide on recurrent bone stress injury3 years

    The investigators will evaluate the long-term effects of the administration of teriparatide by following the study enrollees for a 1-year period after the completion of the study drug. The team will determine the incidence of additional or recurrent bone stress injury. This will be defined as a diagnosed bone stress injury by a physician, advanced practice provider or PCM (primary care manager) utilizing radiographic studies including: plain radiograph, MRI, and/or bone scan.